0 11 Lymphocytes Lymphocyte NNP 12 16 from from IN 17 20 CML CML NNP 21 29 patients patient NNS 30 34 lack lack VBP 35 36 a a DT 37 39 47 47 CD 40 43 kDa kda NN 44 50 factor factor NN 51 57 having have VBG 58 66 affinity affinity NN 67 70 for for IN 71 72 a a DT 73 80 genomic genomic JJ 81 87 sterol sterol NN 88 98 regulatory regulatory JJ 99 107 sequence sequence NN 107 108 . . . 110 118 Deranged deranged JJ 119 127 cellular cellular JJ 128 139 cholesterol cholesterol NN 140 151 homeostasis homeostasis NN 152 155 has have VBZ 156 160 been be VBN 161 167 widely widely RB 168 178 recognized recognize VBN 179 181 in in IN 182 185 the the DT 186 196 initiation initiation NN 197 199 as as RB 200 204 well well RB 205 207 as as IN 208 219 progression progression NN 220 222 of of IN 223 230 various various JJ 231 236 types type NNS 237 239 of of IN 240 247 cancers cancer NNS 248 257 including include VBG 258 265 chronic chronic JJ 266 273 myeloid myeloid JJ 274 283 leukaemia leukaemia NN 284 285 ( ( ( 285 288 CML CML NNP 288 289 ) ) ) 289 290 . . . 291 296 Since since IN 297 300 the the DT 301 306 human human JJ 307 314 genomic genomic JJ 315 321 sterol sterol NN 322 332 regulatory regulatory JJ 333 340 element element NN 341 342 ( ( ( 342 345 SRE SRE NNP 345 346 ) ) ) 347 350 has have VBZ 351 355 been be VBN 356 361 shown show VBN 362 364 to to TO 365 373 regulate regulate VB 374 381 various various JJ 382 385 key key JJ 386 391 genes gene NNS 392 400 involved involve VBN 401 403 in in IN 404 408 this this DT 409 419 phenomenon phenomenon NN 419 420 , , , 421 424 the the DT 425 432 present present JJ 433 438 study study NN 439 447 revealed reveal VBD 448 451 the the DT 452 461 existence existence NN 462 464 of of IN 465 466 a a DT 467 473 unique unique JJ 474 476 47 47 CD 477 480 kDa kda NN 481 488 protein protein NN 489 495 factor factor NN 496 502 having have VBG 503 511 affinity affinity NN 512 515 for for IN 516 520 this this DT 521 524 SRE SRE NNP 525 533 sequence sequence NN 534 536 in in IN 537 548 lymphocytes lymphocyte NNS 549 553 from from IN 554 560 normal normal JJ 561 569 subjects subject NNS 569 570 , , , 571 573 as as RB 574 578 well well RB 579 581 as as IN 582 585 its its PRP$ 586 593 absence absence NN 594 596 in in IN 597 608 lymphocytes lymphocyte NNS 609 613 from from IN 614 623 untreated untreated JJ 624 627 CML CML NNP 628 636 patients patient NNS 636 637 . . . 638 645 However however RB 645 646 , , , 647 651 this this DT 652 658 factor factor NN 659 667 appeared appear VBD 668 672 when when WRB 673 678 these these DT 679 682 CML CML NNP 683 691 patients patient NNS 692 700 achieved achieve VBD 701 709 complete complete JJ 710 724 haematological haematological JJ 725 734 remission remission NN 735 736 ( ( ( 736 739 CHR CHR NNP 739 740 ) ) ) 741 748 through through IN 749 765 alpha-interferon alpha-interferon NN 766 773 therapy therapy NN 773 774 . . . 775 786 Furthermore furthermore RB 786 787 , , , 788 790 an an DT 791 798 inverse inverse JJ 799 811 relationship relationship NN 812 815 was be VBD 816 820 also also RB 821 829 observed observe VBN 830 837 between between IN 838 841 the the DT 842 845 LDL LDL NNP 846 854 receptor receptor NN 855 859 gene gene NN 860 870 expression expression NN 871 873 at at IN 874 877 the the DT 878 893 transcriptional transcriptional JJ 894 899 level level NN 900 903 and and CC 904 907 the the DT 908 915 binding binding NN 916 924 affinity affinity NN 925 927 of of IN 928 932 this this DT 933 935 47 47 CD 936 939 kDa kda NN 940 947 protein protein NN 948 954 factor factor NN 955 957 to to TO 958 961 the the DT 962 965 SRE SRE NNP 966 974 sequence sequence NN 974 975 . . . 976 981 Based base VBN 982 986 upon upon IN 987 992 these these DT 993 1000 results result NNS 1001 1003 we we PRP 1004 1011 propose propose VBP 1012 1016 that that IN 1017 1021 this this DT 1022 1028 factor factor NN 1029 1032 may may MD 1033 1037 have have VB 1038 1039 a a DT 1040 1044 role role NN 1045 1047 in in IN 1048 1063 pathophysiology pathophysiology NN 1064 1066 of of IN 1067 1074 chronic chronic JJ 1075 1082 myeloid myeloid JJ 1083 1092 leukaemia leukaemia NN 1092 1093 . . .